Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract

British Journal of Cancer

Volumn 90, Issue 9, 2004, Pages 1715-1719

  Hsu, C ^a   Shen, Y C ^a   Yang, C H ^a   Yeh, K H ^a   Lu, Y S ^a   Hsu, C H ^a   Liu, H T ^b   Li, C C ^c   Chen, J S ^d   Wu, C Y ^a   Cheng, A L ^a,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

5 fluorouracil; Biliary tract carcinoma; Gemcitabine; Leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 2642516411     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601796     Document Type: Article

References (33)

1. Andre T, Louvet C, Amu P, Selle F, Tournigand C, Garcia ML, Avenin D, Maindraults F, Provent S, de Gramont A (2001) A phase II study of gemcitabine and oxaliplatln (gemox) in advanced blliary adenocarcinoma (ABA). Preliminary results. Eur J Cancer 37(Suppl 6): 19 (abstrct A60)
2. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L (1991) A phase II study of weekly 24-h infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630
3. Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvement is survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
4. Carraro S, Servienti PJ, Bruno MF, Odena M, Roca E, Jovtis S, Felci N, Araujo C (2001) Gemcitabine and cisplatin in locally advanced or metastatic gallbladder and bile duct adenocarcinomas. Proc Am Soc Clin Oncol 20: 2333 (abstract)
5. de Gramont A, Louvet C, Andre T, Tournigand C, Krulik M (1998) A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 34: 619-626
6. de Groen PC, Larusso NF, Gunderson LL, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341: 1368-1378
7. Doval DC, Sekhon JS, Fuloria J, Gupta SK, Vaid AK, Gupta S, Shukla VK (2001) Gemcitabine and cisplatin in chemotherapy-naive, unresectable gallbladder cancer: a large multicenter, phase II study. Proc Am Soc Clin Oncol 20: 622 (abstract)
8. Falkson G, Macintyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54: 965-969
9. Fleming ID (ed) (1997) American Joint Committee on Cancer Staging Manual, 5th edn, Philadelphia: Lippincott, Willaims & Wilkins
10. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK (1997) Maximum tolerated dose defined for single agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol 15: 310-316
11. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M (2001) Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19: 4088-4091, (correspondence)
12. Harvey JH, Smith FP, Sehien PS (1984) 5-Fluorouracil, mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2: 1245-1248
13. Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34: 977-986
14. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL (1997) Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: an effective and low-toxic regimen for patients with poor general condition. Oncology 54: 275-280
15. Kaye SB (1994) Gemcitabine: current status of phase I and phase II trails. J Clin Oncol 12: 1527-1531
16. Koehne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B, Schmoll HJ (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-h infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418-426
17. Koehne CH, Wils J, Lorenz M, Schoeffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rueckle H, Lichinitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-h infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestival Group study 40952. J Clin Oncol 21: 3721-3728
18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
19. Oberfield RA, Rossi RL (1988) The role of chemotherapy in the treatment of bile duct cancer. World J Surg 12: 105-108
20. O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB (2001) Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-1-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-h infusion schedule - an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study. J Clin Oncol 19: 2413-2421
21. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M (1994) A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51: 515-517
22. Raderer M, Hejna M.H.L, Valencak J.B, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W (1999) Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin-C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177-180
23. Saltz LB (2003) Another study of how to give fluorouracil? J Clin Oncol 21: 3711-3712 (editorial)
24. Scheithauer W (2002) Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29(Suppl 20): 40-45
25. Shuster JJ (1991) Median follow-up in clinical trials. J Clin Oncol 9: 191-192 (letter)
26. Simon R (2001) Design and conduct of clinical trials. In Cancer: Principle and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) pp 521-538. Philadelphia: Lippincott, Williams & Wilkins
27. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, Duez N, Sahmoud T (1993) Phase II trial of mitomycin C in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cooperative Group Study. Ann Oncol 4: 607-609
28. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408
29. Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9: 1003-1008
30. Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75: 464-465
31. Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH, Chen YC (1997) A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 17: 3867-3872
32. Yeh KH, Yeh SH, Chang YS, Cheng AL (2000a) Minimal toxicity to myeloid progenitor cells of weekly 24-h infusion of 5-fluorouracil: direct evidence from colony forming unti-granulocyte and monocyte (CFU-GM) clonogenic assay. Pharmacol Toxicol 86: 122-124
33. Yeh KH, Yeh SH, Hsu CH, Wang TM, Ma IF, Cheng AL (2000b) Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 83: 1510-1515